United States: Amgen v. Sandoz The Supreme Courts First Biosimilars Ruling

In a unanimous decision issued on June 12, 2017, the Supreme Court for the first time interpreted key provisions of the 2010 Biologics Price Competition and Innovation Act ("BPCIA"). See Sandoz Inc. v. Amgen Inc., No. 15-1195 (U.S. June 12, 2017). The Court's decision grants more flexibility to biosimilar companies and filers of abbreviated Biologics License Applications ("aBLAs"), holding that (1) a reference product sponsor is not entitled to injunctive relief under federal law for an applicant's refusal to provide a copy of its aBLA and manufacturing information during the information exchange period contemplated by the BPCIA, and (2) an applicant may provide statutory 180-day pre-launch notice of commercial marketing before its proposed biosimilar product is licensed by FDA. An overview of the parties' oral arguments before the Court on these issues can be found here.

The Federal Circuit Holdings on Appeal to the Supreme Court

The Amgen v. Sandoz proceedings arose out of Sandoz's filing an aBLA with FDA to market a biosimilar version of Amgen's approved Neupogen (filgrastim) biologic. As we previously discussed, the Federal Circuit opinion below had held that:

  1. aBLA applicants do not violate the BPCIA by "opting out" of the BPCIA's "patent dance" information exchange procedures and choosing not to provide a reference product sponsor, like Amgen, with a copy of their aBLAs and manufacturing information as described in 42 U.S.C. § 262(l)(2)(A); and
  2. aBLA applicants may not provide the reference product sponsor with 180-day pre-launch notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A) until after FDA approves the biosimilar product.

The Supreme Court affirmed the Federal Circuit on the first issue, albeit on different grounds, and reversed on the second issue.

The BPCIA "Patent Dance" Information Exchange is Optional, and a Biosimilar Manufacturer's Failure to Participate is Not a Violation of the BPCIA

The Supreme Court affirmed the Federal Circuit by holding that a reference product sponsor may not pursue an injunction under federal law if the aBLA applicant refuses to engage in the BPCIA's "patent dance" information exchange. Specifically at issue was § 262(l)(2)(A) of the BPCIA, which instructs that an aBLA applicant "shall provide to the reference product sponsor a copy of the [aBLA] application" and information describing the biosimilar product manufacturing processes.

Despite agreeing with the Federal Circuit's holding on this question, the Supreme Court took issue with the Federal Circuit's reasoning. An applicant's failure to comply with § 262(l)(2)(A), the Court held, is not an act of artificial infringement under 35 U.S.C. § 271(e)(4). Instead, such failure simply provides the reference product sponsor with a different and exclusive remedy under § 262(l)(9)(C). That section allows the sponsor to bring an immediate declaratory judgment action for patent infringement under § 271(e)(2)(C)(ii). No injunctive relief is permitted under the BPCIA for such an act. The Court also observed that in contrast with § 262(l)(2)(A), a different provision of the BPCIA, § 262(l)(1)(H), expressly allows for an injunctive remedy. Thus, the Court held, Congress clearly knew how to provide for injunctive relief in the event of an applicant's failure to follow BPCIA provisions, but deliberately chose not to provide such relief when an aBLA applicant fails to engage in the § 262(l)(2)(A) information exchange.

While the biosimilar applicant may refuse to participate in the § 262(l)(2)(A) information exchange without subjecting itself to an injunction, that refusal is not without consequence. For example, the reference product sponsor's ability to bring a declaratory judgment action under § 262(l)(9)(C) on "any patent that claims the biological product or a use of the biological product" is no longer limited to the applicant-controlled "list" of patents. The reference product sponsor, and not the biosimilar applicant, is thus more able to control the scope and timing of the ensuing patent litigation.

The Court remanded to the lower courts to determine whether failure to engage in the § 262(l)(2)(A) information exchange is "unlawful" under California's unfair competition law. The Court offered no opinion on that issue of state law, but did vacate the opinion below because it improperly considered only the BPCIA, rather than California law.

aBLA Applicants May Provide 180-day Notice of Commercial Marketing Before FDA Approves a Biosimilar Product

The Court also reversed the Federal Circuit by holding that an aBLA applicant need not wait until FDA actually licenses a biosimilar product before providing the reference product sponsor with the 180-day notice of commercial marketing required under § 262(l)(8)(A). Rejecting Amgen's proposed statutory construction, the Court based its holding on the fact that the plain language of § 262(l)(8)(A) imposes only a single timing requirement, namely to provide notice at least 180 days before first commercial marketing. Section 262(l)(8)(A) makes no reference to the date of FDA biosimilar licensing, the Court held, and thus does not require that notice only follow FDA approval. Once again, the Court pointed to language elsewhere in the BPCIA to establish that Congress knew how to impose such a requirement but deliberately chose not to in this case. For example, § 262(l)(8)(B) plainly allows a preliminary injunction suit after receiving notice and before first commercial marketing.

The Court recognized that policy considerations support arguments for and against requiring biosimilar approval before allowing the 180-day notice, but noted that even persuasive policy considerations must take a backseat to the BPCIA's "plain language" in this case.

Supreme Court Provides Some Clarity, But BPCIA Litigation Likely to Continue

The Supreme Court's ruling clarifies that aBLA applicants may completely refuse to engage in the BPCIA's "patent dance" information exchange, and need not wait for FDA approval of the biosimilar product before providing the reference product sponsor with 180-day notice of commercial marketing.

It remains to be seen how aBLA applicants and reference product sponsors will respond to the Court's ruling. The 180-day notice ruling, for example, will likely have a significant impact on the timing of the "second phase" of BPCIA litigation. For many biologic products, this means the first and second "phases" of BPCIA litigation may be effectively merged. But not all applicants may wish to engage in litigation on all of a sponsor's listed patents any earlier than necessary.

Moreover, as Justice Breyer's concurrence explains, even the issues resolved by the Court's ruling may not stay settled for good. Justice Breyer wrote separately to point out that FDA may, after "greater experience administering" the BPCIA, have authority to depart from or modify the Court's interpretation.

Stay tuned for further coverage of this and other BPCIA issues making their way through the courts.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions